fashion -WSS

fashion

author：focus 2025-09-30 01:13:30 - browse：68

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Food makers to regulators: Ultra

WSS

How medical schools plan to diversify without affirmative action

Food makers tried to stack nutrition panel with preferred experts

'Cuddling' is just what the doctor ordered for a 200

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Taylor Swift shares sweet moment with Kobe Bryant's daughter Bianka at Eras Tour concert

White House touts steps to stem shortages of cancer treatments

hotspot

fashion

explore

Affirmative action in medical school literally saved lives

Special counsel alerts court to Trump’s social media post

Sports medicine is finally prioritizing gender equality

Acelyrin, a rare IPO success, stumbles in its first big test

At least 13 dead in Texas as scorching temps continue

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Psychedelics group wrestles with new pharma identity

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

Drug repurposing or repositioning? The language matters

Parkland mass shooting to be reenacted for lawsuit

leisure time

Hospitals consider fixing cancer drug shortages on their own

How medical schools plan to diversify without affirmative action

Lifetime voting ban for felony convictions struck down in Mississippi

Does Medicare's free annual wellness visit do any good?

Will the IRA bring competition to the biologics market?

Food makers to regulators: Ultra

entertainment

explore

explore

hotspot